Ignite Creation Date:
2024-05-06 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06214052
Status:
COMPLETED
Last Update Posted:
2024-05-09
First Post:
2024-01-09
Brief Title:
VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
Sponsor:
ViiV Healthcare
Organization:
ViiV Healthcare
Study Overview
Official Title:
A Phase 2a Randomized Double-Blind Sponsor Unblinded Placebo-Controlled Study to Investigate the Antiviral Effect Safety Tolerability and Pharmacokinetics of VH4524184 in HIV-1 Infected Treatment Naïve Adults
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety tolerability ability of VH4524184 when given alone to reduce the amount of HIV viral load in people with HIV-1 infection who have never received antiretroviral therapy treatment-naïve Data from this study will be used to decide how VH4524184 can be best included in a full-treatment regimen for HIV-1 in the future
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-507173-18-00 | OTHER | EU CT Number | None |